Government to designate sibutramine as misuse or overuse drug

The Korea Food and Drug Administration is soon considering designating weight loss drugs, such as sibutraime or orlistat, as there is a risk that these medicines may induce overuse or misuse.

The drug agency completed its review of the full study report for SCOUT, which was submitted to the KFDA by the sponsor in March this year, and other relevant information related to sibutramine’s potent...